BioNxt Solutions (OTCMKTS:BNXTF) vs. Dyne Therapeutics (NASDAQ:DYN) Head to Head Review

Dyne Therapeutics (NASDAQ:DYN) and BioNxt Solutions (OTCMKTS:BNXTF) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, institutional ownership, dividends and analyst recommendations.

Analyst Ratings

This is a summary of current ratings for Dyne Therapeutics and BioNxt Solutions, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1	2	13	3	2.95
BioNxt Solutions	0	0	0	0	0.00

Dyne Therapeutics currently has a consensus price target of $38.41, indicating a potential upside of 147.18%. Given Dyne Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Dyne Therapeutics is more favorable than BioNxt Solutions.

Volatility and Risk

Dyne Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, BioNxt Solutions has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.

Insider and Institutional Ownership

96.7% of Dyne Therapeutics shares are held by institutional investors. 14.1% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Dyne Therapeutics and BioNxt Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-66.17%	-56.35%
BioNxt Solutions	N/A	N/A	-709.36%

Valuation and Earnings

This table compares Dyne Therapeutics and BioNxt Solutions”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$317.42 million	($3.66)	-4.25
BioNxt Solutions	$20,000.00	2,861.06	-$3.88 million	($0.04)	-11.68

BioNxt Solutions has higher revenue and earnings than Dyne Therapeutics. BioNxt Solutions is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Dyne Therapeutics beats BioNxt Solutions on 9 of the 13 factors compared between the two stocks.

About Dyne Therapeutics

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

About BioNxt Solutions

BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.